Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.44 |
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27745728 | 1.00 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL8490899 | 0.88 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL30822753 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL3501828 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL28874867 | 0.87 | ADORA3 (0.52) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL3148834 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL442605 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL31392666 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL9489893 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL3503652 | 0.87 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203336-A | Huntingtin (HTT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-114040768-A | Application of inosine in tumor immunotherapy | 免疫闪耀生物科技有限责任公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2020197905-A1 | USE OF INOSINE FOR CANCER IMMUNOTHERAPY | IMMUNOSPARKLE BIOSCIENCE LLC (US) | 2020-10-01 | — | — | WO | claimed |
| US-10736913-B1 | Use of inosine for cancer immunotherapy | IMMUNOSPARKLE BIOSCIENCE LLC (US) | 2020-08-11 | — | — | US | claimed |
| EP-3111800-B1 | DEVICE FOR IDENTIFYING ORAL CONDITIONS | COLGATE PALMOLIVE CO (US) | 2018-11-21 | — | — | EP | claimed |
| CN-104970898-B | For identifying the device of oral conditions | 高露洁-棕榄公司 | 2018-05-29 | — | — | CN | claimed |
| US-9700395-B2 | Device for identifying oral conditions | COLGATE-PALMOLIVE COMPANY (US) | 2017-07-11 | — | — | US | claimed |
| EP-3111800-A1 | DEVICE FOR IDENTIFYING ORAL CONDITIONS | Colgate-Palmolive Company (US) | 2017-01-04 | — | — | EP | claimed |
| CN-104970898-A | DEVICE FOR IDENTIFYING ORAL CONDITIONS | COLGATE PALMOLIVE CO | 2015-10-14 | — | — | CN | claimed |
| US-20150072301-A1 | DEVICE FOR IDENTIFYING ORAL CONDITIONS | COLGATE PALMOLIVE CO (US) | 2015-03-12 | — | — | US | claimed |
| US-20120322023-A1 | DEVICE FOR IDENTIFYING ORAL CONDITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2012-12-20 | — | — | US | claimed |
| CN-102655788-A | Device for identifying oral conditions | COLGATE PALMOLIVE CO | 2012-09-05 | — | — | CN | claimed |
| CN-1188268-A | Method for assessing oxidative stress and its control in humans | NIKKON FOODS CO LTD (JP) | 1998-07-22 | — | — | CN | claimed |
| EP-0845732-A2 | Method for assessing oxidative stress and its control in humans | Nikken Foods Company Limited (JP) | 1998-06-03 | — | — | EP | claimed |
| US-12622640-B2 | Oral data collecting device for diagnosis or prognosis | Emanate Biomedical, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260071179-A1 | PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4682249-A1 | METHOD FOR PRODUCING NERVE CELLS DAMAGED BY OXIDATION STRESS AND APPLICATION THEREOF | FUJIFILM Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-5849782-A | Methods of inhibiting neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0845732-A2 | Method for assessing oxidative stress and its control in humans | Nikken Foods Company Limited (JP) | 1998-06-03 | — | — | EP | disclosed |
| WO-1996021445-A1 | METHODS OF INHIBITING NEURODEGENERATIVE DISEASES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736913-B1 | Use of inosine for cancer immunotherapy | CD47, ICOS, HAVCR2 | ADORA3 51/4885TK1 300/4885PNP 879/4885 |
| US-12622640-B2 | Oral data collecting device for diagnosis or prognosis | TAS2R30, TAS2R39, TAS2R46 | ADORA3 2450/4885TK1 903/4885PNP 3457/4885 |
| US-20260071179-A1 | PRODUCTION METHOD OF NERVE CELLS DAMAGED BY OXIDATIVE STRESS AND APPLICATIONS THEREOF | AIFM2, AIFM1, FECH | ADORA3 3143/4885TK1 3257/4885PNP 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.